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Implications for Nursing Care
Multiple Sclerosis
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A 69-year-old female diagnosed with MS 27 year ago.  Symptoms began as 
weakness in the left leg that would come and go.  The weakness slowly spread to 
the right side of the body.  The patient went to the doctor when the right side 
went completely weak.  At the beginning of the disease process the patient was 
not on any medications.  When there was an exacerbation, the patient would be 
off work for two or three weeks.  Resting aided in recovery.  No medications 
were taken at this time.  
The first MS drug tried was Betaseron, for approximately 10 years.  During 
this time there would be exacerbations approximately every two years.  Rest and 
IV steroids would aid in recovery.  
The patient was taken off of Betaseron with a new neurologist due to the side 
effect of depression, which the patient was experiencing.  The medication 
Copaxone was taken, but the results were not desired, so it was discontinued.  
For several years the patient was not on any medication for MS.  Two years ago, 
Ocrevus was started.  The patient is very pleased with the results.  There are no 
new lesions on the current MRI.   
The main symptom the patient has is weakness in legs which has caused 
progressive loss of function leading to using a progression from a cane, to a 
walker, then to a wheelchair for mobility.  Fatigue, incontinence, depression, and 
feeling useless are other symptoms the patient reports. 
Aggravating factors are heat, humidity, stress, and negative people.  Relieving 
factors are working on crafts, being outside when able, bible study, reading, and 
watching tv.  There is no family history of MS.  
Multiple sclerosis (MS) is an 
advanced pathophysiological 
disease that is relevant to 
advanced practice nursing. It is the 
“most common immune-mediated 
inflammatory demyelinating 
disease of the central nervous 
system” (Olek & Howard, 2019).  
The exact cause of MS is still 
unknown; however, it is 
characterized by exacerbations of 
neurological dysfunction due to 
inflammatory demyelination 
(Huang, Chen, & Zhang, 2017).  
Consequently, the treatment of 
MS requires a multi-disciplinary 
approach, with nurses at the heart 
of the team. Hence, an advanced 
practice nurse will need to be able 
to recognize the signs and 
symptoms of MS for a proper 
diagnosis and must be familiar 
with the current trends in patient 
management and treatments of 
the disease.  This help to support 
and advocate for best available 
intervention strategies acceptable 
to the patient and relevant to 
decrease chronic pathology.  
Reason for 
Study
• MS	is	the	leading	cause	of	neurologic	disability	in	young	to	middle-aged	adults.		This	causes	an	important	socio-economic	impact	(D’haeseleer,	et	al.,	2015)	which	nurses	can	help	address	with	proper	referral	and	treatment.
• Due	to	the	unpredictable	and	highly	variable	course	MS	takes	it	is	important	for	the	multi-disciplinary	team	to	be	well	informed	of	the	pathophysiology	of	MS	(Feys et	al.,	2016).
Signs & SymptomsThe	signs	and	symptoms	of	MS	vary	depending	on	the	affected	part	of	the	Central	Nervous	System	(CNS)	(Arneth,	2019).
• White	matter	plaque	formation	(Arneth,	2019)
• Axonal	injury	(Arneth,	2019)
• Demyelination	(Arneth,	2019)
• Sensory	loss	(Huang	et	al.,	2017)
• Visual	disturbances	(Huang	et	al.,	2017)
• Double	vision	(Huang	et	al.,	2017)
• Muscle	weakness	(Huang	et	al.,	2017)
• Ataxia	(Huang	et	al.,	2017)
• Impaired	balance	(Huang	et	al.,	2017)
• Fatigue	(Žiaková,	Čáp,	Miertová,	&	Gurková,	2019)
• Exhaustion	(Žiaková et	al.,	2019)
• Bowel	and	bladder	dysfunction	(Arneth,	2019)
• Depression	(Kamm,	Uitdehagg,	&	Polman,	2014)
• Sleep	disorders	(Kamm,	Uitdehagg,	&	Polman,	2014)
• Spasticity	(Kamm	et	al.,	2014)
• Tremor		(Kamm	et	al.,	2014)
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Around	the	globe	around	2.3	million	people	are	diagnosed	with	MS	(Arneth,	2019).		The	complex	pathophysiology	and	insidious	nature	of	the	progression	of	the	disease	makes	care	complicated.		While	all	patients	show	destruction	of	the	myelin	on	the	axons,	symptoms	vary	widely	depending	on	the	location	of	the	plaques.		The	ability	to	interpret	the	exacerbation	signs	and	symptoms	of	MS	is	an	important	competency	to	possess.		Nurses	work	as	part	of	a	multi- disciplinary	team	to	provide	a	wide	range	of	treatment	options.		Excellent	nursing	care	focuses	on	the	patient’s	quality	of	life.
Conclusions
The	exact	cause	of	MS	is	unknown.			Many	theories	exist	to	answer	this	question,	several	of	which	are	listed	below.		
• One	widely	accepted	theory	for	the	pathogenesis	of	MS	is	that	it	begins	as	an	inflammatory	immune-medicated	disorder	(Olek &	Mowry,	2019).		
• B	cells	through	several	mechanisms	including	the	establishment	of	ectopic	lymphoid	follicles	within	the	CNS	(Huang	et	al.,	2017).		
• B	cells	are	also	thought	to	affect	MS	development	by	targeting	autoantigens	(Arneth,	2019).
• Cytokine	and	antibody	production	is	another	theory	(Huang	et	al.,	2017).
• Tumor	necrosis	factor-alpha	inhibitors	could	have	a	role	in	the	cause	of	MS	(Olek &	Mowry,	2019).
• One	theory	suggests	that	the	Epstein-Barr	Virus	(EBV)	could	cause	MS.		The	upregulation	of	antigen	specific	cytotoxic	T	cells	stay	in	the	body	for	several	years	after	the	initial	infection.		Autoimmunity	results	when	the	cytotoxic	T	cells	target	self-peptides	in	the	CNS	(Spagnuolo,	Piavis,	&	Williams,	2017).
• While	it	is	not	understood	what	exact	role	heredity	plays	in	developing	MS,	there	are	some	genes	that	lead	to	an	increased	risk.		Specific	genes	related	to	inflammation	have	been	found	with	an	increased	risk	of	MS.		People	who	have	dysregulation	of	T-cell	differentiation	have	a	higher	prevalence	of	MS	(Spagnuolo	et	al.,	2017).
• Dendritic	cells	(DC)	are	part	of	the	pathogenesis	of	MS.		Different	types	are	found	in	white	matter	and	cerebrospinal	fluid	of	people	who	have	MS	(Spagnuolo	et	al.,	2017).		
Underlying Pathophysiology
In	MS	plaques	form	in	the	CNS	and	combined	with	inflammation,	demyelination,	axonal	injury	and	axonal	loss	are	the	defining	processes	of	the	disease	(Huang	et	al.,	2017).		The	plaques	are	expressed	in	all	of	the	forms	of	MS.		Over	time	the	plaques	disappear	and	return	at	different	intervals	(Huang	et,	al.	2017).		The	location	of	the	plaques	dictates	the	symptoms	expressed	and	amount	of	disability	the	patient	experiences.		The	disease	is	progressive	in	nature	and	has	different,	defined	types.			A	person	is	first	diagnosed	when	a	sudden	onset	of	a	neurological	symptom	compels	a	visit	to	the	primary	health	care	provider	(Huang	et	al.,	2017).		The	relapsing	remitting	type	of	MS	is	exhibited	by	periods	when	the	person	is	symptomatic	followed	by	times	of	no	symptoms.		Recovery	from	these	episodes	can	be	complete	or	partial	(Huang	et	al.,	2017).		This	type	of	MS	often	turns	into	a	type	of	the	disease	called	secondary	progressive.		This	is	characterized	by	continuous	irreversible	neurological	impairment	between	relapses	(Huang	et	al.,	2017).		In	primary	progressive	MS	the	patient	has	a	gradually	progressive	course	from	the	time	of	diagnosis	(Huang	et	al.	2017).		There	are	no	periods	of	remission.		Progressive-relapsing	MS	is	characterized	by	a	pattern	of	relapses	while	neurologic	functions	are	worsening	from	the	onset	of	symptoms	(Sevim,	2016).
Significance of Pathophysiology
The	unknown	exact	cause	of	MS,	the	wide	variety	in	symptoms,	and	the	unpredictability	of	the	disease	course	has	significant	implications	for	the	patient	and	the	nurse.		Feys et	al.	(2016)	suggests	a	multi-disciplinary	approach	to	adequately	meet	all	of	the	patients	complex	and	often	changing	needs.		This	team	can	include	a	neurologist,	nurse,	primary	care	provider,	other	specialists,	and	professionals	outside	of	the	health	care	sector	(Feys et	al.,	2016).		Many	new	management	options	have	been	found	in	the	past	20	years	(D’haeseleer,	2015).		Nurses	need	to	keep	up	with	changes	in	treatments	to	help	educate	patients	not	only	about	current	options,	but	side	effects	as	well.		The	focus	of	the	care	needs	to	be	the	improvement	of	quality	of	life	and	the	patient’s	ability	to	work	(Kamm	et	al.,	2014).		Suggestions	for	nurses	can	include	linking	the	patient	with	accessibility	resources	or	occupational	therapy.			People	who	have	MS	noted	the	feeling	of	invisibility	(Žiaková,	Čáp,	Miertová,	&	Gurková,	2019).	The	nurse	needs	to	keep	this	in	mind	and	address	questions	to	the	patient,	not	a	care	giver.		The	patient	also	might	have	cognitive	or	speech	delays	and	would	need	more	time	to	answer	questions.		The	patients	care	giver	is	also	affected,	indirectly	and	must	be	considered	by	the	nurse	as	well	(Feys et	al.,	2016).
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